Abbreviations ABCP: atezolizumab + bevacizumab + carboplatin + paclitaxel, ALK: anaplastic lymphoma kinase, BSC: best supportive care, EGFR: epidermal growth factor receptor, NSCLC: non-small cell lung cancer, Neg.: negative, PD-L1: programmed death-ligand 1, PDC: platinum-doublet chemotherapy, PEM: Pemetrexed, PLAT: platinum chemotherapy, Pos.: positive, ROS1: C-ros oncogene 1, SOC: Standard of care TA: technology appraisal, TKI: tyrosine kinase inhibitors, TPS: tumour proportion score. This evidence concerns the gene CD274 and non-small cell lung carcinoma.